Recent findings about the deep scattering layer

Sound scattering observations in deep water are reported for the frequency range from 2 to 20 kc. An explosive sound source was employed to give a sound having high acoustic pressures throughout the frequency range. The receiver was directed vertically downward in the water; the recorder allowed simultaneous recording over several frequency bands...

Narrative of Chain cruise #43 : February - August 1964

Originally issued as Reference No. 65-9, series later renamed WHOI-.On CHAIN Cruise 43, 15 February to 21 August 1964, geophysical and geological observations were made in the North Atlantic Ocean, the Mediterranean and Red Seas, and the Western part of the Indian Ocean, along the track Woods Hole - Ceuta (Spanish Africa) - La Spezia - Port Said - Aden - Victoria (Seychelles Islands) - Port Louis (Mauritius) - Victoria (Seychelles Islands) - Port Said - Beirut - La Spezia - Monaco - Plymouth (England) - Woods Hole. This report contains (1) a narrative of the cruise, (2) a list of stations, (3) statements of the scientific objectives of the cruise, (4) a summary of the geological and geophysical observations, (5) end-of-cruise reports on equipment and some phases of the research program, and (6) a selection of bottom photographs. WHOI Ref. No. 64-51 contains a detailed navigational plot of the entire cruise, including soundings and the locations of other observations.This cruise was supported by the National Science Foundation under Grant GP-2370 and Submitted to the Office of Naval Research under Contract Nonr-4029(00) NR 260-101

Seismic refraction measurements in the Atlantic Ocean Basin (Part one)

A reversed seismic refraction measurement was made 120 miles northwest of Bermuda (400 miles east of Cape Hatteras) in 2,800 fathoms of water. A velocity of 24,800 feet per second (7.58 km/sec.) for the second layer was identified with the ultrabasic layer of earthquake seismology. Assuming a velocity of 5,600 feet per second (1.70 km/sec.), clearly indicated by earlier measurements, a thickness of 4,500 feet was obtained for the sedimentary layer. The granitic and intermediate layers were absent

The Importance of Ethics and Ethical Leadership in the Accounting Profession

The emergence of the twenty-first century was plagued with extensive, evasive and disheartening leadership failures. Despite the accounting profession’s standards of professional ethics, it was also tainted with ethical leadership indiscretions during this era. In response to these ethical leadership failings, renewed interest in developing accounting professionals with strong ethical principles and ethical leadership behaviors has emerged. In many firms training and development of ethical behavior is now at the forefront of the firm’s communications and professional development efforts. The question remains however, can the profession instill in its members the importance of ethical conduct? Can ethical leaders be developed that model and monitor ethical behavior? In response to the call for leaders who are ethical and moral, this research examined a model that examines ethical leadership and its impact on leader effectiveness for leaders within the accounting industry. The analysis shows that ethical and transformational leadership make incremental independent contributions in explaining leader effectiveness. The study comments on how the findings that ethically and morally focused leaders may impact the accounting profession and restore an industry tarnished with accusations of unethical behavior to one that regains its original prominence based on consistent, moral, ethical, and effective leaders

What an Agile Leader Does: The Group Dynamics Perspective

When large industrial organizations change to (or start with) an agile approach to operations, managers and some employees are supposed to be “agile leaders” often without being given a clear definition of what that comprises when building agile teams. An inductive thematic analysis was used to investigate what 15 appointed leaders actually do and perceive as challenges regarding group dynamics working with an agile approach. Team maturity, Team design, and Culture and mindset were all categories of challenges related to group dynamics that the practitioners face and manage in their work-life that are not explicitly mentioned in the more process-focused agile transformation frameworks. The results suggest that leader mitigation of these three aspects of group dynamics is essential to the success of an agile transformation

Heritability of DNA-damage-induced apoptosis and its relationship with age in lymphocytes from female twins

Apoptosis is a physiological form of cell death important in normal processes such as morphogenesis and the functioning of the immune system. In addition, defects in the apoptotic process play a major role in a number of important areas of disease, such as autoimmune diseases and cancer. DNA-damage-induced apoptosis plays a vital role in the maintenance of genomic stability by the removal of damaged cells. Previous studies of the apoptotic response (AR) to radiation-induced DNA damage of lymphoid cells from individuals carrying germline TP53 mutations have demonstrated a defective AR compared with normal controls. We have also previously demonstrated that AR is reduced as individuals age. Results from the current study on 108 twins aged 18–80 years confirm these earlier findings that the AR of lymphoid cells to DNA damage is significantly reduced with increasing age. In addition this twin study shows, for the first time, that DNA-damage-induced AR has a strong degree of heritability of 81% (95% confidence interval 67–89%). The vital role of DNA-damage-induced apoptosis in maintaining genetic stability, its relationship with age and its strong heritability underline the importance of this area of biology and suggest areas for further study

A comprehensive map of molecular drug targets.

The success of mechanism-based drug discovery depends on the definition of the drug target. This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clinical efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups. However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development. Here, we present an updated comprehensive map of molecular targets of approved drugs. We curate a total of 893 human and pathogen-derived biomolecules through which 1,578 US FDA-approved drugs act. These biomolecules include 667 human-genome-derived proteins targeted by drugs for human disease. Analysis of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncology. We explore the relationships between bioactivity class and clinical success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes. Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of molecular therapeutics and present conventions for deconvoluting the complexities of molecular pharmacology and drug efficacy

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types